|
Characteristics of patients with JIA |
|||
| JIA |
Oligoarticular JIA |
Polyarticular JIA |
|
|
|
|||
| Number |
36 |
16 (44%) |
20 (56%) |
| Male/Female |
9/27 (25%/75%) |
3/13 (19%/81%) |
6/14 (30%/70%) |
| Age range in years (median) |
3.5–18.9 (11.4) |
3.5–16.6 (11.7) |
4.9–18.9 (10.9) |
| Disease durationa |
5.1 (3.3) |
5.2 (4.0) |
5.0 (2.8) |
| Disease activity (active/remission) |
22/14 (61%/39%) |
9/7 (56%/44%) |
13/7 (65%/35%) |
| RF-positive |
2 (6%) |
0 |
2 (10%) |
| ANA-positive |
21 (58%) |
11 (69%) |
10 (50%) |
| Uveitis |
3 (8%) |
2 (13%) |
1 (5%) |
| NSAID use |
30 (83%) |
11 (69%) |
19 (95%) |
| Sulfasalazine and/or methotrexate use |
10 (28%) |
2 (13%) |
8 (40%) |
|
aExpressed in years as mean (standard deviation). Disease duration at the time of sampling was defined as the time that passed since the first disease-related symptom (arthritis). The presence of joint swelling or limitation of movement with either pain on movement or tenderness defined active disease. The absence of joint swelling or limitation of movement with either pain on movement or tenderness defined disease remission. None of the patients was treated with prednisone, anti-tumor necrosis factor-α, or anti-interleukin-1 therapy. ANA, anti-nuclear antigen; JIA, juvenile idiopathic arthritis; NSAID, non-steroidal anti-inflammatory drug; RF, rheumatoid factor. | |||
Kamphuis et al. Arthritis Research & Therapy 2006 8:R178 doi:10.1186/ar2088 |
|||